Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Using microarray-based subtyping methods for breast cancer in the era of high-throughput RNA sequencing

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Harnessing data science to advance radiation oncology

    Publikation: Bidrag til tidsskriftReviewpeer review

  2. Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Molecular subtype classification of urothelial carcinoma in Lynch syndrome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. A novel homozygous GFI1B variant in 2 sisters with thrombocytopenia and severe bleeding tendency

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs)

    Publikation: Bidrag til tidsskriftReviewpeer review

  3. Multiple endocrine neoplasia type 2: A reveiw

    Publikation: Bidrag til tidsskriftReviewpeer review

Vis graf over relationer

Breast cancer is a highly heterogeneous disease that can be classified into multiple subtypes based on the tumor transcriptome. Most of the subtyping schemes used in clinics today are derived from analyses of microarray data from thousands of different tumors together with clinical data for the patients from which the tumors were isolated. However, RNA sequencing (RNA-Seq) is gradually replacing microarrays as the preferred transcriptomics platform, and although transcript abundances measured by the two different technologies are largely compatible, subtyping methods developed for probe-based microarray data are incompatible with RNA-Seq as input data. Here, we present an RNA-Seq data processing pipeline, which relies on the mapping of sequencing reads to the probe set target sequences instead of the human reference genome, thereby enabling probe-based subtyping of breast cancer tumor tissue using sequencing-based transcriptomics. By analyzing 66 breast cancer tumors for which gene expression was measured using both microarrays and RNA-Seq, we show that RNA-Seq data can be directly compared to microarray data using our pipeline. Additionally, we demonstrate that the established subtyping method CITBCMST (Guedj et al., ), which relies on a 375 probe set-signature to classify samples into the six subtypes basL, lumA, lumB, lumC, mApo, and normL, can be applied without further modifications. This pipeline enables a seamless transition to sequencing-based transcriptomics for future clinical purposes.

OriginalsprogEngelsk
TidsskriftMolecular Oncology
Vol/bind12
Udgave nummer12
Sider (fra-til)2136-2146
Antal sider11
ISSN1574-7891
DOI
StatusUdgivet - dec. 2018

ID: 56673402